Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9899468 | 0.89 | HCRTR1 (0.36) | HCRTR1HCRTR2 | |
| SCHEMBL9899326 | 0.77 | CRHR1 (0.39) | HCRTR1HCRTR2 | |
| SCHEMBL9899569 | 0.70 | KMT2A (0.38) | — | |
| SCHEMBL9899437 | 0.70 | HCRTR1 (0.40) | SSTR4HCRTR1HCRTR2AGBL2 | |
| SCHEMBL9900511 | 0.69 | HCRTR1 (0.37) | HCRTR1HCRTR2 | |
| SCHEMBL1119706 | 0.67 | HCRTR1 (0.38) | HCRTR1HCRTR2 | |
| SCHEMBL6519608 | 0.67 | HCRTR1 (0.41) | HCRTR1HCRTR2 | |
| SCHEMBL6523847 | 0.67 | NPC1 (0.41) | HCRTR1HCRTR2 | |
| SCHEMBL9928405 | 0.66 | MAPK1 (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL9928400 | 0.66 | HCRTR1 (0.39) | SSTR4HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470525-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | Glaxo Group Limited (GB) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149711-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED | 2012-06-14 | — | — | US | disclosed |
| US-20120149711-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED | 2012-06-14 | — | — | US | disclosed |
| US-20120149711-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149711-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, OXTR | SSTR4 80/4885HCRTR1 2/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.